Stockscreener 앱 받기
0.6702
3.57%
-0.0248
시간 외 거래:
.67
-0.0002
-0.03%
전일 마감가:
$0.695
열려 있는:
$0.7
하루 거래량:
738.52K
Relative Volume:
0.32
시가총액:
$152.64M
수익:
$8.95M
순이익/손실:
$-21.49M
주가수익비율:
-5.585
EPS:
-0.12
순현금흐름:
$-29.24M
1주 성능:
+11.57%
1개월 성능:
+15.04%
6개월 성능:
-22.52%
1년 성능:
-36.17%
1일 변동 폭
$0.665
$0.71
1주일 범위
$0.598
$0.73
52주 변동 폭
$0.481
$1.61
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.6702 | 152.64M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
BlackRock, Inc. Increases Stake in Lineage Cell Therapeutics Inc. - GuruFocus.com
Stem Cell Therapy Market Types, Applications, Share, Growth - openPR
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference - BioSpace
Lineage Cell Therapeutics Inc (LCTX) Stock: Navigating a Year of Volatility - The InvestChronicle
Cell Therapy Pioneer Lineage to Showcase Latest Neurological Breakthroughs at Major Healthcare Conference - StockTitan
Lineage Cell Therapeutics Inc (LCTX) stock on the rise: An overview - US Post News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from HC Wainwright - MarketBeat
Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.60, Up/Down -4.12 - The Dwinnex
Defender Capital LLC. Has $3 Million Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at HC Wainwright - Defense World
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics - Benzinga
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Broadwood Partners acquires $6 million in Lineage Cell Therapeutics shares By Investing.com - Investing.com Canada
Broadwood Partners acquires $6 million in Lineage Cell Therapeutics shares - Investing.com
JPMorgan Chase & Co. Boosts Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering - BioSpace
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Barclays PLC Boosts Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Rises By 13.5% - MarketBeat
Cell Therapy Manufacturing Market Trends, Innovations, - openPR
Jane Street Group LLC Cuts Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Maxim Group Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion Landscape - GlobeNewswire
Barclays PLC Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Geode Capital Management LLC Raises Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Issues Letter to Stockholders - BioSpace
Lineage Cell Therapeutics outlines 2025 strategy - Investing.com
Lineage Cell Therapeutics Secures $30M Funding, Extends Runway to 2027 for Cell Therapy Pipeline - StockTitan
Cell Therapy Manufacturing Market Generated Opportunities, - openPR
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital - Yahoo Finance
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts - Benzinga
D. Boral Capital Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1%Here's What Happened - MarketBeat
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround - Yahoo Finance
BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 - Marketscreener.com
LCTX stock touches 52-week low at $0.5 amid market challenges - Investing.com
Cell Therapy Manufacturing Market Growth in Future Scope - openPR
Lineage Cell Therapeutics FY2024 EPS Lifted by HC Wainwright - MarketBeat
HC Wainwright Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Stem cell therapy companies take different roads to reproducibility - BioCentury
Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com
Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio? - Yahoo Finance
Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio? - Insider Monkey
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lineage Cell Therapeutics Inc 주식 (LCTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Howe Jill Ann | Chief Financial Officer |
Nov 26 '24 |
Buy |
0.59 |
15,000 |
8,850 |
25,500 |
| Samuel George A. III | General Counsel |
Nov 26 '24 |
Buy |
0.60 |
15,000 |
9,000 |
22,184 |
| Mulroy Michael H. | Director |
Nov 22 '24 |
Buy |
0.57 |
40,000 |
22,640 |
298,555 |
| Culley Brian M | President and CEO |
Nov 21 '24 |
Buy |
0.60 |
40,000 |
24,000 |
194,842 |
| Howe Jill Ann | Chief Financial Officer |
Aug 16 '24 |
Buy |
0.89 |
10,500 |
9,345 |
10,500 |
| Culley Brian M | President and CEO |
May 24 '24 |
Buy |
1.05 |
10,000 |
10,500 |
154,842 |
| BAILEY DON M | Director |
Feb 08 '24 |
Buy |
1.04 |
96,155 |
100,001 |
158,801 |
1.09%
자본화:
|
볼륨(24시간):